Characteristics at HT of the 32 patients with transformed MZL and univariable analysis for death from any cause
| Characteristic . | Category . | No. (%) . | HR (CI 95%) . | P value . |
|---|---|---|---|---|
| Age at transformation | ≥70 y | 12 (37.5) | 3.57 (1.34-9.48) | .011 |
| Time to HT | <1 y | 8 (25.0) | 1.10 (0.40-3.00) | .86 |
| Ann Arbor stage | III-IV | 24 (80.0) | 0.58 (0.20-1.71) | .32 |
| Missing data | 2 | |||
| Bone marrow involvement | Yes | 9 (39.1) | 0.37 (0.09-1.41) | .14 |
| Missing data | 9 | |||
| ECOG performance status | ≥2 | 10 (34.5) | 2.22 (0.81-6.08) | .12 |
| Missing data | 3 | |||
| LDH | Greater than normal | 11 (57.9) | 1.14 (0.18-7.16) | .89 |
| Missing data | 13 | |||
| Hemoglobin | <12 g/dL | 12 (54.5) | 2.90 (0.75-11.26) | .13 |
| Missing data | 10 | |||
| Lymphocytes | <1000 per mm3 | 8 (36.4) | 0.38 (0.08-1.86) | .23 |
| Missing data | 10 | |||
| Platelets | <100 109/L | 3 (13.6) | - | |
| Missing data | 10 |
| Characteristic . | Category . | No. (%) . | HR (CI 95%) . | P value . |
|---|---|---|---|---|
| Age at transformation | ≥70 y | 12 (37.5) | 3.57 (1.34-9.48) | .011 |
| Time to HT | <1 y | 8 (25.0) | 1.10 (0.40-3.00) | .86 |
| Ann Arbor stage | III-IV | 24 (80.0) | 0.58 (0.20-1.71) | .32 |
| Missing data | 2 | |||
| Bone marrow involvement | Yes | 9 (39.1) | 0.37 (0.09-1.41) | .14 |
| Missing data | 9 | |||
| ECOG performance status | ≥2 | 10 (34.5) | 2.22 (0.81-6.08) | .12 |
| Missing data | 3 | |||
| LDH | Greater than normal | 11 (57.9) | 1.14 (0.18-7.16) | .89 |
| Missing data | 13 | |||
| Hemoglobin | <12 g/dL | 12 (54.5) | 2.90 (0.75-11.26) | .13 |
| Missing data | 10 | |||
| Lymphocytes | <1000 per mm3 | 8 (36.4) | 0.38 (0.08-1.86) | .23 |
| Missing data | 10 | |||
| Platelets | <100 109/L | 3 (13.6) | - | |
| Missing data | 10 |
ECOG, Eastern Cooperative Oncology Group.